Announcements Trials
Browse Landscape

Phase

Phase 2 56Phase 1/2 23Phase 1 12Phase 3 11Phase 4 2Phase 2/3 2Phase NA 1Phase EARLY_PHASE1 1

Status

Active not recruiting 4Recruiting 3Completed 3Unknown 2Terminated 2Not yet recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Carboplatin 9Paclitaxel 8Gemcitabine 8Cisplatin 8Cyclophosphamide 7Fluorouracil 6Docetaxel 5Capecitabine 5Granulocyte Colony-Stimulating Factor 4Etoposide 4Vinorelbine 3Stem Cell Transplantation 3Radiotherapy 3Pemetrexed 3Melphalan 3Leucovorin 3Filgrastim 3Erlotinib Hydrochloride 3Bone Marrow Transplantation 3Bevacizumab 3umbralisib 2ublituximab 2pembrolizumab 2peginterferon alfa-2b 2fludarabine 2Whole-Body Irradiation 2Trastuzumab 2Transplantation, Homologous 2Surveys and Questionnaires 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Trastuzumab × Clear all
NCT00169104 2018-07-20

Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function

Dartmouth-Hitchcock Medical Center

Phase 2/3 Terminated
23 enrolled 10 charts
Breast

Breast Neoplasms

NCT02213744 2017-01-06

HERMIONE

Merrimack Pharmaceuticals

Phase 2/3 Terminated
113 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡